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Alternative pre-mRNA splicing (AS) widely expands proteome diversity through the combinatorial assembly of
exons. The analysis of AS on a large scale, by using splice-sensitive microarrays, is a highly efficient method to
detect the majority of known and predicted alternative transcripts for a given gene. The response to targeted
anticancer therapies cannot easily be anticipated without prior knowledge of the expression, by the tumor, of target
proteins or genes. To analyze, in depth, transcript structure and levels for genes involved in these responses,
including AKT1-3, HER1-4, HIF1A, PIK3CA, PIK3R1-2, VEGFA-D and PIR, we engineered a dedicated gene chip with
coverage of an average 185 probes per gene and, especially, exon-exon junction probes. As a proof of concept, we
demonstrated the ability of such a chip to detect the effects of over-expressed SRSF2 RNA binding protein on the
structure and abundance of mRNA products in H358 lung cancer cells conditionally over-expressing SRSF2. Major
splicing changes were observed, including in HER1/EGFR pre-mRNA, which were also seen in human lung cancer
samples over-expressing the SRSF2 protein. In addition, we showed that variations in HER1/EGFR pre-mRNA splicing
triggered by SRSF2 overexpression in H358 cells resulted in a drop in HER1/EGFR protein level, which correlated
with increased sensitivity to gefitinib, an EGFR tyrosine kinase inhibitor. We propose, therefore, that this novel tool
could be especially relevant for clinical applications, with the aim to predict the response before treatment.
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Alternative pre-mRNA splicing (AS) occurs for an esti-
mated 90% of genes in the human genome [1], with
remarkable repercussions on proteome diversity [2]. The
outcome of AS strongly depends on context. Hence, AS
occurs to allow the onset of development or differenti-
ation programs, to participate in cancer occurrence or
progression, and to develop integrated responses to stress-
ful conditions [3-5]. Importantly, AS transcripts may
encode alternative protein isoforms, which quite often dis-
play distinct or even opposite functions, such as for the
pro- or anti-apoptotic caspases or Bcl-2 family proteins
[6-8]. In addition, AS may also lead to the assembly of* Correspondence: laurent.corcos@inserm.fr
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reproduction in any medium, provided the orshort-lived mRNAs targeted to degradation through the
nonsense mediated decay (NMD) system [9]. However,
even if NMD transcripts do not encode proteins, their oc-
currence may modify the ratio of mRNA isoforms, poten-
tially affecting protein synthesis outcome [10].
Analytical tools to study AS on a large scale have been
developed by Affymetrix™, with the Human Exon 1.0 ST
arrays, also referred to as splice-sensitive microarrays,
which allow surveying known and predicted AS events
throughout the transcriptome [11,12]. Recently, deep se-
quencing methods have made it possible to determine
both mRNA levels and structure [13-15]. Nevertheless,
the mathematical tools necessary to decipher the structure
and amount of mRNA species identified by sequencing
are still under constant development [16,17]. In addition,
a recent comparison between RNA-Seq and Affymetrix™
Exon arrays has revealed that the chip method was moreLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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also demonstrated that microarray technologies could be
used as a reliable routine diagnostic tool, thanks to the de-
velopment of a small custom-made microarray able to
predict disease outcome in breast cancer patients [19].
Following on that path, the aim of the present study was
to develop a customized microarray enabling to detect
both known and predictable AS events for a small number
of genes involved in tumor growth and in the response to
targeted anticancer therapies. To take advantage of the
DNA chip experimental setup, we wished to improve the
methodology by increasing the amount of probes, includ-
ing exon-exon junction probes absent from Affymetrix™
Exon arrays, which would allow detecting virtually all AS
events that could occur in this subset of genes.
Targeted anticancer therapies include drugs, such as
inhibitors of tyrosine kinase or monoclonal antibodies
(mAbs), which oppose cell growth signaling or tumor
blood vessel development, promote the specific death of
cancer cells, or stimulate the immune system. Among
specific molecules with which targeted therapies inter-
fere, the HER (human epidermal growth factor receptor)
family regulates cell growth, survival, adhesion, migration
and differentiation. Trastuzumab (Herceptin™), which was
FDA-approved in 2000, was the first treatment using a hu-
manized mAb to target the receptor tyrosine kinase
encoded by the HER2 oncogene, and is mainly used to
treat breast cancers over-expressing this receptor [20,21].
Cetuximab (Erbitux™) and gefitinib (Iressa™) target HER1/
EGFR (epithelial growth factor receptor), or its tyrosine
kinase activity, respectively, and bevacizumab (Avastin™)
blunts VEGF-A (vascular endothelial growth factor A)
activity upon binding to the Gly88 residue from the extra-
cellular domain [22]. AS transcript variants have been
characterized for all these targets, especially for VEGFA
[23-25], and could account for part of the inefficacy of the
responses to mAbs. The PIK3/Akt pathway is a major sig-
naling cascade downstream of the receptor tyrosine ki-
nases. In addition, VEGFA expression is regulated by the
hypoxia factor HIF-1α. The analyzed genes on this custom
microarray include AKT1-3, HER1-4, HIF1A, PIK3CA,
PIK3R1-2,VEGFA-D, and PIR that lies close to the VEGFD
locus and could be fused to VEGFD upon read through
transcription. Collectively, these genes can lead to the as-
sembly of more than 100 mRNAs with protein-coding
capacity (http://www.ensembl.org). Hence, the response to
targeted anticancer therapy will likely depend, at least in
part, on the selection of specific combinations of protein
targets derived from AS events.
In order to validate our custom DNA chip, we took
advantage of the human lung adenocarcinoma H358 cell
line that we previously engineered to conditionally over-
express the pre-mRNA splicing enhancer protein SRSF2,
which controls the splicing of VEGFA pre-mRNA [26], butalso has a role in transcriptional elongation [27]. Positive
results were further validated by specific quantitative RT-
PCR in both H358 cells and human non-small cell lung
carcinoma (NSCLC) samples that we previously showed to
over-express the SRSF2 protein [28]. The repercussion of
altered splicing on the amount of the HER1/EGFR protein
and the response to gefitinib were analyzed in H358 cells.
Results
Validation of the splice-inducing ability of SRSF2
Using an E1A-based plasmid minigene in transient trans-
fection experiments, we analyzed the splice-inducing abil-
ity of SRSF2 (Additional file 1: Figure S1). There was an
up-regulation of the 13S PCR band associated with a
down-regulation of the 9S band, indicating that SRSF2
over-expression could modify the balance of E1A-derived
transcripts, as originally described [29].
Cross validation with 44 k Agilent microarray
To analyze the gene expression changes triggered by
over-expression of SRSF2 in H358 lung cancer cells, we
performed an analysis using 44 k Agilent™ microarrays.
These data have been deposited in NCBI’s Gene Expres-
sion Omnibus and are accessible through GEO Series
accession number GSE50467. A lot of genes were differ-
entially expressed between SRSF2-over-expressing H358
lung cancer cells and H358 control cells (1,709 deregu-
lated probes; ≥ 2.0 FC, P-value ≤ 0.05 by t-test with FDR;
Additional file 2: Table S1), corresponding to 52% up-
and 48% down-regulations. Hence, in addition to its
already reported role in the regulation of VEGFA spli-
cing, over-expression of SRSF2 led to the regulation of
transcript abundance of many additional genes, includ-
ing genes present on the 15 k custom chip (Additional
file 3: Table S2), as demonstrated with the 44 k Agilent™
microarrays.
Validation of the labeling method: comparison of the
15 k custom and 44 k Agilent microarrays
The labeled cRNA yield and the specific activity of cya-
nine3 were examined for each of three labeling experi-
ments (Additional file 4: Table S3). A comparison of the
15 k custom and 44 k commercial microarrays, with re-
spect to Agilent™ probes present on both chips, was per-
formed in order to validate the use of the labeling method
with the 15 k custom microarray. The number of 15 k
replicates using Quick Amp labeling was equal to 4 for
each condition (control or SRSF2 over-expression), and
the number of 44 k replicates was equal to 6 for each con-
dition. We found that 313 Agilent™ probes (corresponding
to 16% of the total number of Agilent™ probes on the 15 k
chip) were deregulated on the 15 k custom microarray
(≥ 1.5 FC, P-value ≤ 0.05), among which 310 (99%) had
the same type of (up- or down-) regulation on the 44 k
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Pearson correlation between expression signals of these
313 common genes led to a coefficient of 0.89. There-
fore, it was considered that Quick Amp labeling was val-
idated for the 15 k custom microarray.
Detection of the mRNA regulation
We analyzed the expression of the 16 selected genes
present in the 15 k custom microarray, considering the
expression of all custom probes for each gene (Table 1).
Four genes (HER4, PIK3CA, PIK3R1 and VEGFD) were
not expressed; five genes (AKT2, AKT3, HER2, PIK3R2
and VEGFC) were not differentially expressed; five genes
(AKT1, HER3, HIF1A, PIR and VEGFB) were slightly
down-regulated (≤ 1.5 FC, P-value ≤ 0.05); HER1/EGFR
was more strongly down-regulated (≥ 1.5 FC, P-value ≤
0.05), and VEGFA was up-regulated (≥ 1.5 FC, P-value ≤
0.05) in SRSF2-over-expressing H358 lung cancer cells in
comparison to H358 control cells. A good concordance
between the 15 k and 44 k microarray results was found: 8
out of the 16 genes present in 15 k custom chip were
deregulated on 44 k chips (≥ 1.1 FC, P-value ≤ 0.05), con-
sidering Agilent™ probes, and showed the same type of
regulation on the 15 k chip, considering custom probes
(Additional file 3: Table S2).
Regulation events among the expressed genes
The bioinformatics analysis of the 15 k custom microarray
showed that 30 custom probe sets from expressed genesTable 1 Gene expression changes in SRSF2-over-expressing H
Gene regulation Gene symbol Control condition intensity
Up-regulated VEGFA 9.25
Down-regulated HER1/EGFR 5.01














The expression and the regulation of the 16 genes were analyzed on the 15 k custo
to control cells. Some genes were not expressed; others were not differentially expr
one gene (HER1/EGFR) was more strongly down-regulated (≥ 1.5 FC, P-value ≤ 0.05)
condition (≥ 1.5 FC, P-value ≤ 0.05).were differentially expressed in SRSF2-over-expressing
H358 lung cancer cells in comparison to H358 control
cells (≥ 1.5 FC, P-value ≤ 0.05; Table 2). The low expressed
deregulated probe sets were not considered. The regula-
tion events corresponded to 70% down- and 30% up-
regulations, mostly affecting cassette exons, but also
5′-untranslated regions and terminal or donor splice sites,
of 9 genes among the 12 expressed genes (AKT2, AKT3,
HER1/EGFR, HER2, HER3, HIF1A, PIK3R2, VEGFA and
VEGFB). Regulations were associated with a high, medium
or low confidence, depending on the regulation of probes
close to the deregulated probe sets. A list of supporting
evidences (Additional file 6: Table S5) was defined corre-
sponding to the regulations that were not always statisti-
cally relevant, but confirmed the deregulation of some
probe sets. Consequently, these regulations were associ-
ated with a high confidence. On the contrary, the confi-
dence was considered as low if neighboring probes were
not deregulated or if their regulation was opposite. The
regulations associated with a high fold-change and corre-
sponding to unknown and predicted pre-mRNA splicing
events could be of special interest.
Validation of regulation events by real-time polymerase
chain reaction
Quantitative RT-PCR was used to measure the expression
of 9 genes deregulated on both the 15 k custom and the
44 k commercial microarrays, and the differential expres-
sion of all genes in SRSF2-over-expressing H358 lung358 lung adenocarcinoma cells
SRSF2 condition intensity Regulation Fold-change P-value
9.99 up 1.67 3.38E-08
4.11 down 1.87 3.65E-06
1.78 down 1.47 3.98E-03
6.06 down 1.33 2.04E-04
6.62 down 1.32 1.82E-03
7.68 down 1.28 8.15E-05
7.48 down 1.28 2.56E-04
4.19 up 1.19 1.62E-01
1.91 down 1.06 6.18E-01
4.81 down 1.05 4.01E-01
5.74 down 1.05 5.57E-01
5.89 down 1.01 9.03E-01
1.89 up 1.45 3.71E-02
0.98 up 1.07 8.23E-02
0.69 up 1.03 4.87E-01
1.78 down 1.01 8.58E-01
m microarray in SRSF2-over-expressing H358 lung cancer cells in comparison
essed. Five genes were slightly down-regulated (≤ 1.5 FC, P-value ≤ 0.05), and
. Only one gene (VEGFA) was up-regulated in the SRSF2 over-expression
Table 2 Deregulated probe sets in SRSF2-over-expressing H358 lung adenocarcinoma cells
Gene symbol Region name Region type Confidence Regulation Fold-change P-value RT-PCR
AKT2 je14_e15_5p_region Junction Low Down 1.63 1.36E-02 No
AKT3 je7_e8 Junction High Down 5.99 2.07E-05 Yes
AKT3 e8 Exon High Down 4.19 4.10E-03 Yes
HER1/EGFR je16_e19 Junction High Down 3.66 1.42E-03 Yes
HER1/EGFR predict_exon_1_2-10 Exon Medium Up 33.98 0.00E + 00 No
HER1/EGFR est_1_2 Exon Medium Up 17.35 1.00E-09 No
HER1/EGFR predict_exon_2_3-1 Exon Medium Up 4.97 5.51E-05 No
HER1/EGFR e26 Exon Medium Down 2.64 2.30E-03 No
HER1/EGFR ae1_donor_alter Donor_alter Medium Up 5.55 5.40E-03 No
HER1/EGFR je14_e15 Junction Low Down 1.87 1.05E-02 No
HER1/EGFR je12_e13 Junction Low Down 1.76 1.13E-02 No
HER2 ae10_prom_alter Prom_alter Medium Down 2.73 2.32E-02 No
HER3 je22_ae23_acceptor_alter_l Junction Low Up 1.68 3.33E-02 No
HIF1A je10_e11 junction High Down 1.87 1.66E-05 Yes
HIF1A e10 Exon High Down 1.62 3.65E-02 Yes
HIF1A e9 Exon High Down 1.56 4.78E-02 Yes
HIF1A e5 Exon Low Down 2.07 1.23E-02 No
HIF1A je1_5p_region_ae3_acceptor_alter Junction Low Down 1.56 1.64E-02 No
HIF1A je14_e16 Junction Low Up 2.22 2.08E-02 No
PIK3R2 e6 Exon High Down 1.97 7.61E-05 No
PIK3R2 je5_e6 Junction High Down 3.95 3.98E-04 No
PIK3R2 je7_e8 Junction Low Down 1.68 2.14E-03 No
PIK3R2 e9 Exon Low Down 1.74 3.34E-03 No
PIK3R2 je2_e3 Junction Low Down 1.58 4.36E-02 No
VEGFA e4_term_alter Term_alter High Up 10.18 7.43E-08 Yes
VEGFA ae6_donor_alter_2 Donor_alter High Down 2.44 4.18E-07 Yes
VEGFA jae6_donor_alter_2_e7 Junction High Down 1.93 4.96E-03 Yes
VEGFA ae7_donor_alter Donor_alter High Up 1.80 6.98E-04 Yes
VEGFA e7 Exon Low Up 1.50 4.00E-04 No
VEGFB je2_e3 Junction Low Down 1.62 6.47E-05 No
A list of the 30 differentially expressed and deregulated custom probe sets (≥ 1.5 FC, P-value ≤ 0.05) from expressed genes among the 16 analyzed genes in
SRSF2-over-expressing lung cancer cells in comparison to control cells on the 15 k custom microarray is presented. The regulations were associated with a high,
medium or low confidence, depending on the regulation of probes in the vicinity of the deregulated probe sets. According to the results with a high confidence
(in bold characters), we expect an up-regulation of exon 7 and a down-regulation of exon 8 for AKT3, a multiple exon skipping for HER1/EGFR, a skipping of both
exons 9 and 10 for HIF1A, an alternative polyadenylation in intron 4, and alternative donor sites for exons 6 and 7 for VEGFA.
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lyzed with RNA isolated independently from that used for
chip hybridization (Additional file 7: Table S6). These
results confirmed the validity of our experimental ap-
proach used to analyze the 15 k custom microarray. Ten
out of the 30 deregulated probe sets were selected accord-
ing to their high confidence (Table 2), and concerned 4
genes, including AKT3, HER1/EGFR, HIF1A and VEGFA
(Figure 1). The results of quantitative RT-PCR experi-
ments are shown in Table 3. Relative mRNA levels were
normalized to control gene mRNA levels or a fold-change
was calculated comparing to a reference event. For HER1/EGFR, we showed a down-regulation of one of the tran-
scripts (last exon > e20) in SRSF2-over-expressing H358
lung cancer cells in comparison to H358 control cells. For
AKT3, we validated the up-regulation of exon 7 and the
down-regulation of exon 8; that is because the e7+/e8-
transcript was over-expressed as compared to the e7+/e8+
transcript including both exons. For HIF1A, the up-
regulation for two (e9+/e10- and e9-/e10-) of the three al-
ternative transcripts compared to the e9+/e10+ transcript
led us to conclude that both exons 9 and 10 were down-
regulated. For VEGFA, we validated the alternative polya-
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Figure 1 Alternative splicing events induced by SRSF2 over-expression in H358 lung adenocarcinoma cells. The AKT3-derived mRNAs in
the exon 6–9 region, the HIF1A-derived mRNAs in the exon 8–11 region, and the various last exons for HER1/EGFR and VEGFA are depicted. The
arrows show the position of the primers designed and used for validation of the splicing events detected by the 15 k custom gene chip.
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transcript (last exon > e5). We also confirmed the alterna-
tive donor site for the exon 6 by an up-regulation of the
“alternative donor e6” transcript in comparison with the
“constitutive donor e6” transcript.
HER1/EGFR protein expression analysis
The 15 k custom microarray predicted multiple exon
skipping in the 3′ region of HER1/EGFR in SRSF2-over-
expressing H358 lung cancer cells, which was confirmed
by quantitative RT-PCR. These observations led us to
test whether these splicing events would have an impact
on the amount of the HER1/EGFR protein. Western
blotting analysis was performed using various anti-EGFR
antibodies directed against the N-terminal (31G7) or the
C-terminal (D38B1) portion of the protein, as well as
against the phosphorylated active form of EGFR (P-HER1/
EGFR-Tyr1068). The results demonstrated that SRSF2overexpression in H358 cells led to a decrease in EGFR
protein amount, as detected using all antibodies (Figure 2).
These data suggested that SRSF2-regulated EGFR pre-
mRNA splicing strongly affects EGFR protein expression.
In addition, H358 cells express a wild-type EGFR pro-
tein and are resistant to apoptosis in response to EGFR
tyrosine kinase inhibitors such as gefitinib. In order to de-
termine if SRSF2-induced EGFR protein down-regulation
could modify the response of H358 cells to gefitinib, we
performed a dose–response of the drug in the presence
or absence of SRSF2 induction (Figure 3). As expected,
a 24 hours-treatment with gefitinib significantly pre-
vented EGFR-Tyr1068 phosphorylation in these cells,
but only partially engaged apoptosis at the higher concen-
tration, which was detected by poly-ADP ribose polymer-
ase (PARP) processing. However, caspase-3 was never
activated in gefitinib-treated cells. Of note, at the highest
gefitinib concentration, a reduction in the amount of total
Table 3 Quantitative RT-PCR validation in SRSF2-over-expressing H358 lung adenocarcinoma cells
SRSF2 Condition vs. Control condition
Gene Calculation Transcript Expression Observed transcript regulation Expected transcript regulation
HER1/EGFR Relative expression Last exon = e17 n/a Not expressed No expression
Last exon = e18 0.91 Not regulated Over-expression
Last exon > e20 0.42 Under-expressed Under-expression
AKT3 Fold-change e7+ e8- vs. e7+ e8+ 1.46 Over-expression of e7+ e8- Over-expression of exon 7 and
under-expression of exon 8
e7- e8+ vs. e7+ e8+ −1.19 No regulation of e7- e8+
e7- e8- vs. e7+ e8+ n/a No expression of e7- e8-
HIF1A Fold-change e9+ e10- vs. e9+ e10+ 1.91 Over-expression of e9+ e10- Under-expression of exon 10
e9- e10+ vs. e9+ e10+ −1.52 Under-expression of e9- e10+ Under-expression of exon 10
e9- e10- vs. e9+ e10+ 1.82 Over-expression of e9- e10- Under-expression of exons
9 and 10
VEGFA Fold-change Last exon = e4 vs. last exon > e5 18.93 Over-expression of “last exon = e4” Over-expression of exon 4
VEGFA Fold-change Alternative vs. constitutive
donor e6




The regulation of the 10 selected deregulated custom probe sets was analyzed by quantitative RT-PCR in SRSF2-over-expressing lung cancer cells in comparison
to control cells. Relative mRNA levels were normalized to that of beta-2-microglobulin or a fold-change was calculated comparing to a reference event. The cut-off
value was equal to 1.40. n/a: not available.
Pesson et al. Molecular Cancer 2014, 13:9 Page 6 of 12
http://www.molecular-cancer.com/content/13/1/9EGFR together with the appearance of protein bands of
smaller sizes was observed when using the 31G7 antibody
mainly. These data suggested that EGFR could be proc-
essed in response to high gefitinib doses. Importantly,









Figure 2 Western blot analysis of HER1/EGFR expression. HER1/
EGFR and P-HER1/EGFR (Tyr1068) protein levels were analyzed in
H358/Tet-On/SRSF2 inducible H358 clone by western blotting.
Tubulin was used as a loading control.the decrease in EGFR protein amount was more pro-
nounced and apoptosis was strongly engaged, as evi-
denced by procaspase-3 and PARP cleavages (Figure 3).
This result indicated that SRSF2, through its ability to
control EGFR protein expression, sensitizes H358 cells to
the apoptosis induced by EGFR tyrosine kinase inhibitors.
Alternative splicing events in lung cancer biopsy samples
Finally, we aimed at extending some of our in vitro data
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Figure 3 Effects of SRSF2 overexpression on the response to
gefitinib in H358 lung adenocarcinoma cells. The H358/Tet-On/
SRSF2 inducible H358 clone was treated or not for 24 hours with
increasing concentrations of gefitinib as indicated, in the presence
(+) or absence (−) of 1 μg/mL doxycyclin. Western blot analysis was
performed using the indicated antibodies. Apoptosis was analyzed
by the detection of PARP or caspase-3 activation. Tubulin was used
as a loading control.
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may occur in NSCLC [28]. SRSF2 and phospho-SRSF2
expression scores (0–300) were established in 10 NSCLC
biopsy samples (Table 4A) by multiplying the percentage
of labeled tumor cells (0 to 100%) by the staining inten-
sity (0, null; 1, low; 2, moderate; 3, strong). Interestingly,
the three NSCLC samples with the highest SRSF2 and
phospho-SRSF2 scores all displayed a drop in the HER1/
EGFR “last exon > e20” transcript, as determined by quan-
titative RT-PCR, similarly to what occurred in lung cancer
cells. We also analyzed the occurrence of the AKT3,
HIF1A and VEGFA splicing events in NSCLC biopsy sam-
ples (Table 4B). For several samples, we observed an over-
expression of exon 7 and an under-expression of exon 8
of AKT3, and an over-expression of exon 4 and alternative
exon 6 donor splice site for VEGFA. Although the rela-
tionships between SRSF2 status and these splicing events
were less clear in these cases, maybe owing to the smallTable 4 Quantitative RT-PCR validation in non small cell lung
A
Sample 1 2 3
SRSF2 Protein Score 270 270 240
Phospho-SRSF2 Protein Score 270 270 270
B
Non small cell lu
Gene Calculation Transcript 1 2 3
HER1/EGFR Relative expression Last exon = e17 n/a n/a n/a
Last exon = e18 2.69 n/a 1.86
Last exon > e20 0.15 0.29 0.20
AKT3 Fold-change e7+ e8- vs. e7+ e8+ 0.84 1.46 1.16
e7- e8+ vs. e7+ e8+ n/a 1.33 n/a
e7- e8- vs. e7+ e8+ n/a n/a n/a
HIF1A Fold-change e9+ e10- vs. e9+ e10+ 0.63 0.54 1.63
e9- e10+ vs. e9+ e10+ 1.87 n/a n/a
e9- e10- vs. e9+ e10+ 0.57 0.73 1.55
VEGFA Fold-change Last exon = e4 vs.
Last exon > e5
1.33 1.21 1.54
VEGFA Fold-change Alternative vs.
constitutive donor e6
3.50 3.33 5.25
The regulation of the 10 selected deregulated custom probe sets was analysed by q
(patients numbered from 1 to 10). SRSF2 protein expression levels in biopsy sample
was established for SRSF2 and phosphorylated SRSF2 (P-SRSF2). Patients with score
respectively, as compared to normal lung tissues. Patients in bold characters over-e
Relative mRNA levels were normalised to that of beta-2-microglobulin or a fold-cha
to 1.40. n/a: not available. Patients in bold characters over-expressed both SRSF2 annumber of samples, these data validated, in cancer sam-
ples, some of the pre-mRNA splicing events detected in
the SRSF2-over-expressing H538 cell line. The results
were inconclusive for HIF1A, possibly reflecting hetero-
geneity among the NSCLC samples with respect to ex-
pression of this gene.
Discussion
In this study, we designed a custom gene expression
microarray amenable to the study of alternative pre-mRNA
splicing (AS) events of a selection of genes involved in the
response to targeted anticancer therapies. This approach
was preferred to commercial microarrays, such as the Hu-
man Exon 1.0 ST arrays (Affymetrix™) because it allowed a
deeper analysis of AS, in this case of a small number of
genes highly relevant from a clinical standpoint. Indeed, it
is clear that our custom splice-sensitive microarray could
theoretically detect many more events than Affymetrix™carcinoma samples
4 5 6 7 8 9 10
180 160 140 120 100 60 n/a
100 100 90 60 100 40 n/a
ng carcinoma vs. normal lung tissue
4 5 6 7 8 9 10 Observed Transcript
Regulation
n/a 7.17 n/a n/a 16.15 2.52 n/a Not expressed or
over-expressed
2.27 5.13 6.86 2.23 15.16 3.01 66.18 Over-expressed
6.71 6.99 21.45 0.10 5.39 2.46 n/a Over-expressed
or under-expressed
1.37 1.08 1.76 1.29 1.47 1.47 2.28 Over-expression or
no regulation
1.35 n/a n/a n/a 0.38 n/a n/a Low expression of
e7- e8+
n/a n/a n/a n/a n/a n/a n/a No expression of
e7- e8-
1.40 0.79 1.77 0.87 1.22 1.20 1.15 Depending on biopsy
samples
1.06 n/a n/a n/a n/a 1.14 1.77 Depending on biopsy
samples
1.49 0.84 1.88 0.79 1.99 0.76 1.01 Depending on biopsy
samples
1.92 0.84 2.22 10.37 2.73 1.21 1.09 Over-expression or
no regulation
3.99 n/a n/a 19.22 14.29 n/a 45.68 Over-expression
uantitative RT-PCR in 10 non small cell lung carcinoma – normal sample pairs
s were analysed by immunohistochemistry in a previous study. A score (0–300)
s ≥ 150 and > 175 were those over-expressing SRSF2 and P-SRSF2 proteins
xpressed both proteins. n/a: not available.
nge was calculated comparing to a reference event. The cut-off value was equal
d phospho-SRSF2 proteins (see Table 4A).
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number and, especially, exon-exon junction probes, which
were not present on Affymetrix™ Exon Arrays. At a prac-
tical level, several high confidence events revealed, thanks
to exon-exon junction probes, specific splicing events
(Table 2). For example AKT3 je7_e8, HER1/EGFR je16_e19
or HIF1A je10_e11 junction-specific events would have
been undetected on Affymetrix™ arrays. In addition, select-
ing only the high confidence events, the regulations
observed through the chip analysis were confirmed by
quantitative RT-PCR, emphasizing the robustness of both
the technical and the analytical tools used in this study.
Nevertheless, we anticipate that RNA-Seq methodologies
will probably soon be another, reliable, means for charac-
terizing AS throughout the transcriptome [30,31].
We are aware of only one study that used a designed
chip to analyze the occurrence of splicing variants which,
in that case, corresponded to AS events from a single gene,
CIZ1, encoding a Cip1-interacting zinc finger protein [32].
This approach led to the identification of a splice variant
that may be specific for pediatric cancer. There is an
absolute need for predictive biomarkers of therapeutic re-
sponses, especially targeted anticancer therapies, as many
patients do not respond or acquire resistance. For instance,
VEGF-A isoforms may not respond identically to anti-
VEGF-A mAbs (bevacizumab). In fact, the co-occurrence
of both pro-angiogenic (VEGF-Axxx) and anti-angiogenic
(VEGF-Axxxb) splice isoforms might restrict the thera-
peutic response [33-37]. In addition, the occurrence of
soluble EGFR isoforms, as detected in meningiomas [38],
presumably unresponsive to tyrosine kinase inhibitor
therapy, might also dampen the therapeutic response. Fur-
thermore, an exon 4-lacking EGFR variant mRNA was
associated with an increased metastatic potential, a mo-
lecular event that would likely have been detected with our
splice-sensitive microarray [39]. Hence, in addition to pro-
viding a comprehensive picture of splicing events and
potential therapy response, our chip could also help pre-
dicting clinical outcome, based on the detection of pro-
metastatic mRNA species. Nevertheless, beyond the
concept, more predictive studies should be performed
to make our splice-screening methodology an efficient
therapy selecting option.
We showed that SRSF2 has an effect on transcriptional
regulation and on AS of several genes analyzed in this
study. Notably, SRSF2 over-expression modified HER1/Table 5 Comparison of gene coverage between the custom g
Gene Custom array (present study)
Nb probes (exonic/junction) Average probe length (bp
HIF1A 123 (85/38) 42.4
VEGFA 90 (64/26) 42.3
The numbers of probes and their average length are shown for both the HIF1A andEGFR and VEGFA expression in H358 lung cancer cells.
Using patient-derived material, we observed that strong
SRSF2 over-expression in NSCLC is associated with spli-
cing alterations of the HER1/EGFR and VEGFA transcripts,
as predicted from the results in the SRSF2-over-expressing
H358 lung cancer cell line. In addition, HER1/EGFR
splicing events have also been identified in lung adeno-
carcinomas [40], lending support to our results. The
observation that the increase in SRSF2 protein level in-
duced massive procaspase-3 cleavage when associated
with gefitinib in H358 cells, which express wild-type
and non amplified EGFR protein, may be particularly
relevant for patients with lung adenocarcinomas with-
out EGFR mutations, as one of the challenges is to
understand why only some of them respond to EGFR
tyrosine kinase inhibitors.
The expression level of HER1 mRNA, measured through
analysis of the 44 k Agilent™ chip, and the western blotting
analysis of the protein, showed a good correlation in re-
sponse to SRSF2 over-expression. In this specific case, use
of the custom 15 k chip would not have been more pre-
dictive. Nevertheless, it is doubtless that AS, analyzed glo-
bally for all genes from the chip, will provide a lot more
information on both transcript abundance and structure,
allowing defining a prognostic indicator of response to
antibody-based therapy [41]. An important challenge will
be to develop specific antibodies to detect full length or
modified proteins encoded by AS-derived transcripts. Al-
ternatively, mass spectrometry proteomics could be used
to identify and quantify such proteins [42]. The custom
chip analysis could thus ideally supplement immunology-
or proteomics-based approaches aimed at looking for the
expression of protein targets. Our DNA gene chip could
also be used to analyze the effect of other triggers, such as
over-expression or silencing of other splice-modifying pro-
teins, or treatment with drugs, especially anticancer drugs,
which can profoundly affect pre-mRNA splicing [3,43].
Conclusion
Our results describe, for the first time, the design and
validation of a custom splice-sensitive microarray to de-
tect AS events occurring in genes involved in the response
to targeted anticancer therapies. Such an experimental
setup could help clinicians choose anticancer drugs de-
pending on the tumor expression of gene targets with pro-
ficient mRNA structures.ene chip and the Affymetrix™ Exon Array
Affymetrix™ Exon array
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Custom microarray design
A custom microarray was designed taking advantage on the
15 k Whole Human Genome microarray, available from
Agilent™ (Agilent, Massy, France). Among the Agilent™
probes initially loaded on the chip, 11,881 (Additional file 8:
Figure S2) were substituted by custom oligonucleotides,
corresponding to known and predicted exons, introns and
junctions of 16 selected genes, among which there were
members of the AKT (AKT1, AKT2, AKT3), HER (HER1/
EGFR, HER2, HER3, HER4), PIK3 (PIK3CA, PIK3R1,
PIK3R2) and VEGF (VEGFA, VEGFB, VEGFC, VEGFD)
families, but also HIF1A and PIR. On the microarray, the
majority (60%) of custom probes had a length of 40 bp;
some were shorter (down to 22 bp; 8%); others were lon-
ger (up to 50 bp; 26%), which was mostly the case of the
probes for exon-exon junctions. This was especially im-
portant to insure a good detection of alternative 5′ and 3′
splice sites, i.e. alternative exon boundaries. Each custom
probe length was adjusted to 60 bp with linker addition.
The other 3,863 probes on the microarray corresponded
to replicates of commercial Agilent™ probes (genes or con-
trols). As a whole, the expression of 1,967 distinct genes
can be analyzed with our chip.
Cell culture and RNA extraction
The H358 human lung adenocarcinoma cell line was
cultured as described previously [44]. The H358/Tet-On/
SRSF2 inducible clone, conditionally over-expressing the
SRSF2 splicing factor under the control of a Tet-responsive
promoter, has been described previously [44,45]. SRSF2
over-expression was induced upon 24 hours treatment
with 1 μg/mL doxycycline (Additional file 9: Figure S3).
Gefitinib was added to the cells at the indicated final con-
centrations for 24 hours. Total RNA was isolated using the
Trizol reagent (Invitrogen, Cergy-Pontoise, France), ac-
cording to the manufacturer’s instructions. RNA purity
and integrity were determined by measuring the optical
density ratio (A260/A280) and the RNA integrity number
(RIN) using the RNA 6000 Nano LabChip (Agilent™)
and the 2100 Bioanalyzer (Agilent™). Only RNA samples
with a 28S/18S ratio > 1.0 and RIN ≥ 7.0 were used for
microarray analyses.
Plasmid transfection and minigene analysis
An E1A reporter minigene-containing plasmid (pXJ41-
E1A) to study the effect of splice modifier proteins was
used to further validate the effect of SRSF2 protein over-
expression. The plasmid was transfected using Lipofecta-
mine 2000 (Invitrogen). Cells were harvested 24 hours
after transfection, and total RNA was extracted using
the RNeasy Mini kit (Qiagen, Courtabœuf, France),
according to the manufacturer’s instructions. The RNAs
(200 ng) were further used for first-strand cDNAsynthesis with the High-Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems, Courtabœuf, France).
For the detection of E1A splice variants, PCR amplification
was performed using primers 5′-TTT-GGA-CCA-GCT-
GAT-CGA-AG-3′ and 5′-AAG-CTT-GGG-CTG-CAG-
GTC-GA-3′, and PCR products were analyzed by agarose
gel electrophoresis.Microarray hybridization
Analyses of the H358/Tet-On/SRSF2 mRNA content
were performed on both the 15 k custom microarray
and the 44 k Whole Human Genome microarray (Agilent™)
that contains roughly 41,000 probes, providing full
coverage of human transcripts. Double-stranded cDNA
was synthesized from 500 ng of total RNA using the
Quick Amp Labeling kit, One-color, as instructed by
the manufacturer (Agilent™). Labeling with cyanine3-
CTP, fragmentation of cRNA, hybridization and wash-
ing were performed according to the manufacturer’s
instructions. The microarrays were scanned and the
data were extracted with the Agilent™ Feature Extrac-
tion Software.Gene expression analysis
The bioinformatics analysis of the 15 k custom micro-
array data and the comparison of 15 k chip results with
44 k commercial chip results were performed by
GenoSplice technology™. Concerning the 15 k custom
microarray data analysis, data were normalized using
median normalization based on Agilent™ control genes.
Gene expression level was assessed using constitutive
probes only (i.e., probes targeting regions that are not
known to be alternative regions). For each gene of
interest, all possible splicing patterns were defined and
analyzed. All types of alternative events can be analyzed:
alternative first exons, alternative terminal exons, cas-
sette exons, mutually exclusive exons, alternative 5′
donor splice sites, alternative 3′ acceptor splice sites,
and intron retentions. Analyses were performed using
unpaired Student’s t-test on the splicing-index as pre-
viously described [46,47]. Results were considered sta-
tistically significant for unadjusted P-values ≤ 0.05 and
fold-changes ≥ 1.5. After bioinformatics analysis of
microarray data, a manual inspection using the GenoS-
plice EASANA™ interface was conducted to select high-
confidence events. An alternative 44 k bioinformatics
analysis was carried out. Raw gene expression data were
imported into the GeneSpring GX 11.0.2 software pro-
gram (Agilent™). Genes with missing values in more
than 25% of the samples were excluded from the ana-
lysis. A 2-fold cut-off difference was applied to select
the up- and down-regulated genes (P-value ≤ 0.05 by t-
test with Benjamini-Hochberg false discovery rate).
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Regulation events detected in the 15 k custom and 44 k
commercial microarrays were analyzed by quantitative
RT-PCR using RNA isolated from cell preparations
separate from those originally used for microarray
hybridization. Reverse transcription was performed as
instructed by the manufacturer (Applied Biosystems),
as described previously, and quantitative RT-PCR was
conducted using the SYBR GREEN PCR Master Mix
(Applied Biosystems), according to the manufacturer’s
instructions, with an ABI 7300 real-time PCR system
(Applied Biosystems). All determinations were per-
formed in duplicate, normalized against beta-2-micro-
globulin or GAPDH as internal control genes. These
reference transcripts were found to be stable when sur-
veyed in several cell culture systems (data not shown).
The results were expressed as the relative gene expres-
sion using the ΔΔCt method [48]. The fold-change was
also calculated comparing to a reference event. The
sequences of the primers used for the 15 k custom
microarray validation are presented in Additional file
10: Table S7.Protein extraction and western blotting analysis
The antibodies used in this study included anti-SRSF2
(4 F11) from Euromedex, anti-EGFR (31G7) from Invitro-
gen, anti-HER1/EGFR (D38B1) and anti-P-HER1/EGFR
(Tyr1068) (D7A5) from Cell Signaling. For immunoblot-
ting, cells were lysed in RIPA buffer [150 mM NaCl,
50 mM Tris HCl pH 8, 0.1% SDS, 1% Nonidet P40, 0.5%
Na deoxycholate, 0.1 mM PMSF, 2.5 μg/mL pepstatin, 10
μg/mL aprotinin, 5 μg/mL leupeptin, 0.2 mM Na3VO4] for
30 minutes on ice and pelleted. Protein concentration was
determined using the Biorad DC protein assay. Proteins
(40–80 μg) were then separated in 10% SDS-PAGE gels
and electroblotted onto PVDF membranes. Membranes
were incubated overnight at +4°C with primary anti-
bodies and proteins were detected using horseradish
peroxidase-conjugated goat antibodies (Jackson Immu-
noresearch Laboratories, West Grove, PA, USA). After
washing, the blots were revealed using the ECL chemi-
luminescence method (Amersham, Les Ulis, France).
Tubulin was used as a loading control.Human samples
Tissue samples were collected from resection of lung
tumors, and stored for scientific research in a biological
resource repository (Centre de Ressources Biologiques,
CHU Albert Michallon, Grenoble Hospital). National
ethical guidelines were followed. All patients enrolled
provided written informed consent. Tissue banking and
research conduct was approved by the Ministry of Re-
search (approval AC-2010-1129) and by the regional IRB(CPP 5 Sud Est). Protein and RNA samples were isolated
and analysed as described above.Additional files
Additional file 1: Figure S1. E1A splicing assay in response to SRSF2
over-expression. Following transient cell transfection with a SRSF2 expression
plasmid, E1A splice-derived PCR products were electrophoresed through a
2% agarose gel and stained with ethidium bromide. The characteristic PCR
products (9S-13S) are shown.
Additional file 2: Table S1. Deregulated genes on the 44k AgilentTM
microarray in H358 SRSF2-over-expressing cells. Significantly down- and
up-regulated genes in SRSF2-over-expressing H358 lung cancer cells in
comparison to H358 control cells are listed (≥ 2.0 FC, P-value ≤ 0.05 by
t-test with FDR).
Additional file 3: Table S2. Regulation of the 16 selected genes on the
44k AgilentTM microarray in SRSF2-over-expressing H358 cells. The results
for the 8 deregulated genes in SRSF2-over-expressing H358 lung cancer
cells in comparison to H358 control cells on the 44k microarrays are
shown (≥ 1.1 FC, P-value ≤ 0.05 by t-test with FDR). The 44k microarray
results for the 8 deregulated genes showed a good concordance with
the 15k custom microarray results.
Additional file 4: Table S3. Labeling efficiency for hybridization of the
15k custom microarray. The labeled cRNA yield and specific activity of
cyanine3 are shown for each of the three labeling experiments
performed. The cRNA yield should be superior to 1.65 μg, and the
specific activity superior to 9.0 pmol cyanine3 per μg cRNA. The number
of 15k replicates using Quick Amp labeling was 4 for each condition
(control or SRSF2 over-expression), and the number of 44k replicates was
6 (i.e. 2 for each of the three labeling) for each condition.
Additional file 5: Table S4. Comparison of the 15k custom and 44k
AgilentTM microarray results. The results are shown for the AgilentTM
probes present on both chips: 313 probes were deregulated in
SRSF2-over-expressing H358 lung cancer cells in comparison to H358
control cells on the 15k custom chip (≥ 1.5 FC, P-value ≤ 0.05), and 310
had the same type of regulation, considering statistically relevant and
not statistically relevant regulations on the 44k chip (same type of
regulation = 1; other type of regulation = 0).
Additional file 6: Table S5. Supporting evidences. The list of
supporting evidences that confirmed the regulation of some probe sets
in SRSF2-over-expressing H358 lung cancer cells in comparison to H358
control cells is presented.
Additional file 7: Table S6. Quantitative RT-PCR validation. Common
regulation events between the 15k custom and 44k AgilentTM microarrays
were validated by quantitative RT-PCR in SRSF2-over-expressing H358
lung cancer cells in comparison to H358 control cells. Relative mRNA
levels were normalized to that of GAPDH.
Additional file 8: Figure S2. Design of the custom 15k gene chip. The
chip was designed on the backbone of the AgilentTM 15k whole-genome
microarray. The majority of the probes correspond to custom oligonucleotides,
i.e. to both known and predictable sequences of exons, introns and junctions
of 16 genes selected for their biological interest in the response to
targeted anticancer therapies: AKT1-3, HER1-4, HIF1A, PIK3CA, PIK3R1-2,
VEGFA-D and PIR. The resolution of the custom microarray was
decreased in comparison to the Human Exon 1.0 ST array (AffymetrixTM)
from 5 million to 12,000 probes, but the number of probes per gene
was largely increased, from an average of 45 to an average of 185
probes per gene. The expression of 1,967 distinct genes can also be
analyzed thanks to commercial AgilentTM probes.
Additional file 9: Figure S3. Western blot analysis of SRSF2 expression.
SRSF2 protein level was analyzed in H358/Tet-On/SRSF2 inducible clone
by western blotting with the mAb104 monoclonal antibody that
recognizes several phosphorylated SR proteins (SRSF2-6). SRSF2 mRNA
level was also analyzed by quantitative RT-PCR (data not shown). Relative
mRNA level was normalized to that of GAPDH. An 8-fold over-expression
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http://www.molecular-cancer.com/content/13/1/9of SRSF2 mRNA was observed in SRSF2-over-expressing lung cancer cells
in comparison to control cells.
Additional file 10: Table S7. Primers for validation. The sequences of
the primers used for the 15k custom microarray validation are presented.
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